Abstract Purpose: The aim of the current study was to examine the prognostic relevance of the CDKN2A tumor suppressor pathway in gastrointestinal stromal tumors (GIST). Experimental Design: We determined the mRNA expression of p1
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Due to a limited value of most morphologic criteria for assessment of clinical outcome in GISTs, generally accepted prognostic variables are tumor size, mitotic count, proliferation index, and tumor site (1 -3) . Central to the tumorigenesis of GISTs are activating mutations in the proto-oncogene tyrosine-protein kinase Kit (KIT) or platelet-derived growth factor receptor a (PDGFRA; refs. 4, 5) , which are regarded as alternative and mutually exclusive. However, in a subset of so-called wild-type GISTs, no mutation in these two genes can be found. Downstream signaling of constitutively activated oncogenic KIT in GISTs is under current investigation, with implication for distinct activation of AKT, MAPK, and STAT signal transduction pathways (6) .
Recently, functional inactivation of the p16 INK4A transcript at 9p21 via mutation, deletion, or promoter hypermethylation causing loss or down-regulation of the corresponding protein has been identified as an independent unfavorable prognostic factor in GISTs (7 -10) . p16
INK4A is one of two alternate transcripts of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene. The other transcript, p14
ARF , results from an alternative reading frame of the first exon (11) . The CDKN2A gene, with its two transcripts p16 INK4A and p14 ARF , is an important tumor suppressor gene, connecting a complex network of genes ( Fig. 1) , and has a central role in the control of cell proliferation and apoptosis (12) . The p14 ARF gene product inhibits the mouse double minute 2 p53-binding protein (MDM2) from degrading the tumor protein p53 (TP53; ref. 13 ), which prevents uncontrolled proliferation of mutated cells (14) . The p16 INK4A gene product binds to the cyclin-dependent kinase 4 (CDK4), thus inhibiting CDK4 from phosphorylating the retinoblastomaassociated protein (RB1; ref. 15) . Unphosphorylated RB1 binds and blocks the E2F transcription factor 1 (E2F1; ref. 16) , whereas its functional inactivation via CDK-mediated phosphorylation disrupts its ability to suppress E2F1 (17, 18) . When RB1 is phosphorylated, free E2F1 accumulates in the nucleus and initiates S-phase entry via transcription of several genes necessary for DNA synthesis and cell cycle progression (19) . Depending on its status and interacting partners, E2F1 may influence the expression of >1,000 genes involved in proliferation, differentiation, and apoptosis (20, 21) . Hence, E2F1 directs the final step of cell proliferation and occupies a central position in controlling the progression of cells from a quiescent state to proliferation. The release of free E2F1 in intact cells is strictly controlled by its interaction partner RB1 and multiple further negative feedback control mechanisms. Once released, free E2F1 has the ability to up-regulate its own mRNA expression via positive feedback (21) . In human fibroblasts, a simple increased activity of E2F1 has been described to lead to replicative senescence or apoptosis, mainly via p14 ARF transactivation and consecutive TP53 stabilization (22) . Additionally, p14 ARF directly inhibits E2F1 from initiating S-phase entry itself (23) . Pathologic inactivation of RB1 with deregulation of E2F1 induces p16 INK4A expression (24) , foreclosing further CDK-mediated phosphorylation of intact RB1. However, these multiple negative feedback loop control mechanisms have been shown to be at least partially interrupted in many solid tumors (25) . Functional or quantitative loss of p16 INK4A as well as alterations of other genes from the CDKN2A network are believed to be involved in ineffective cell cycle control mechanisms, increased cell proliferation, and progression of a variety of solid tumors.
The aim of the current study was to examine the role of the CDKN2A pathway in tumor progression of GISTs. We determined the mRNA expression of p16 INK4A , p14 ARF , CDK4, RB1, MDM2, TP53, and E2F1 by quantitative reverse transcription-PCR (qRT-PCR) and the immunohistochemical expression of p16 INK4A , p14 ARF , CDK4, and E2F1 in 38 cases of GIST. The prognostic relevance of the genetic findings was evaluated by a cluster analysis using the k-means algorithm, which allows evaluation of distinct mRNA expression patterns of the complete CDKN2A network, and comparison with clinicopathologic features including mutation analysis of KIT and PDGFRA as well as patient outcome.
Materials and Methods
Tumor samples. For this study, snap-frozen as well as formalin-fixed and paraffin wax -embedded tumor samples from primary GISTs of 38 patients were recruited. None of the patients had received imatinib before surgery. Risk of clinically aggressive behavior was evaluated according to the consensus approach published by Fletcher et al. (2) .
Mutation analysis of KIT and PDGFRA genes. For mutation analysis of KIT exons 9, 11, 13, and 17 as well as PDGFRA exons 12 and 18, genomic DNA was extracted from deparaffinized samples of tumor tissue or snap-frozen tissue using spin column purification (Qiagen, Hilden, Germany). PCR was done in 50 AL reaction mixtures containing 0.2 Ag DNA, 10 nmol deoxynucleotide triphosphates, and 20 pmol of each primer, 75 nmol MgCl 2 , 1 unit Platinum Taq polymerase (Invitrogen Life Technologies, Karlsruhe, Germany), and 5 AL of 10Â PCR buffer. Control reactions contained no genomic DNA template. The following primers were used: KIT exon 9 (26), KIT exon 11 (27) , KIT exon 13 (forward/ reverse; refs. 26, 28) , KIT exon 17 (29) , and PDGFRA exons 12 and 18 (5). All PCRs followed the protocol described elsewhere (27) . Direct sequencing of purified PCR products was carried out at a sequencing facility (Seqlab GmbH, Gö ttingen, Germany).
RNA isolation and reverse transcription. After homogenization of the snap-frozen tissue samples with an Ultra Turrax T25 (IKA-Werke GmbH, Staufen, Germany), total RNA was isolated with TRIzol reagent (Invitrogen Life Technologies) according to the manufacturer's manual using f 50 mg frozen tissue per mL TRIzol. Total RNA concentration was quantified with the RNA 6000 Nano LabChip using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Only high-quality total RNA, as confirmed by high peaks for 18S and 28S rRNA, was used. First-strand cDNA was generated from 5 Ag total RNA per sample using the SuperScript II RNase H-Reverse Transcriptase (Invitrogen Life Technologies), including 125 ng random hexamer primers (Invitrogen Life Technologies) and 40 units RNasIn RNase Inhibitor (Promega, Mannheim, Germany). Reverse transcription product was aliquoted in equal volumes and stored at À20jC.
Quantitative reverse transcription-PCR. Gene-specific primers (Table 1) were designed on different exons with a 60jC melting temperature and a length of 18 to 26 bp for PCR products with a length of 50 to 270 bp. PCR was run in 20 AL reactions in triplicates on an iCycler (Bio-Rad Laboratories GmbH, Mü nchen, Germany) using the Eurogentec qPCR Core kit for SYBR Green I (Eurogentec, Seraing, Belgium) and gene-specific primers in a final concentration of 300 nmol/L. The temperature profile consisted of (a) an initial step of 95jC for 10 minutes for Taq activation, (b) 40 cycles of 95jC for 15 seconds and 60jC for 1 minute, and (c) a final melt curve analysis with a temperature ramp from 60jC to 95jC with a heating rate of 3jC/min. PCR efficiencies were calculated with a relative standard curve derived from a cDNA mixture (a 2-fold dilution series with seven measuring points in triplicates) and gave regression coefficients more than 0.95 and reproducible primer-specific efficiencies of 85% to 99%. Gene-specific amplification was confirmed by a single peak in melt curve analysis and a single band in high-resolution agarose gel electrophoresis (SeaKem LE agarose, BMA, Rockland, ME). No template controls (no cDNA in PCR) and genomic controls (no enzyme in reverse transcription reaction) were run for each gene to detect unspecific/genomic amplification or primer dimerization. Relative expression levels in relation to total RNA input were calculated from the relative standard curve as described in refs. 30, 31 and logarithmized to obtain approximately normally distributed data. Additionally, the reference genes 18S, HPRT1, and SDHA (32) could be confirmed to be equivalently expressed within most of the examined clinicopathologic variables as described previously (33) . Therefore, two different and independent methods for interpretation of gene expression data were applicable, which both gave approximately similar results, including significance and fold change levels for differential gene expression.
Immunohistochemistry. Immunohistochemical evaluation of formalin-fixed and paraffin wax -embedded tumor tissue sections was done using the following monoclonal primary antibodies: c-kit (1:400 dilution, DAKOCytomation, Hamburg, Germany), Ki-67 antigen (1:50 dilution, clone Mib1, DAKOCytomation), p16 INK4A (1:100 dilution, JC-8, Quartett, Berlin, Germany), p14 ARF (1:50 dilution, 14P03, Dianova, Hamburg, Germany), CDK4 (1:100 dilution, DCS-35, Chemicon, Temecula, CA), and E2F1 (1:200 dilution, KH95, Dianova). Before incubation with the primary antibody, the slides underwent heat treatment for antigen retrieval (15 minutes at 95jC in 0.1 mol sodium citrate buffer). All primary antibodies were incubated at 4jC overnight, except c-kit and Ki-67, which were incubated at room temperature for 30 minutes. Visualization of the specific primary antibody was done using the DAKO ChemMate Detection kit (DAKOCytomation) with NeoFuchsin as chromogen. The c-kit staining reactions were interpreted in the presence of tissue mast cells or interstitial cells of Cajal as internal positive control. Mitoses were counted in 50 high-power fields (HPF), whereas proliferation rate was estimated as the percentage of Ki-67-positive nuclei from tumor areas with the highest mitotic activity. For the evaluation of p16
INK4A expression, staining of the nuclei or the cytoplasm in >20% of the tumor cells was evaluated as ''p16 INK4A positive'' according to the proposal of Schneider-Stock et al. (7, 10) . As external positive controls, a case of malignant melanoma and a case of squamous cell carcinoma of the cervix were used, which were both strongly positive for p16 INK4A . For p14 ARF , a three-scale semiquantitative scoring for the intensity of the cytoplasmic staining was applied (0, no staining; 1, weak staining; 2, strong staining) using a case of squamous cell carcinoma of the cervix as external positive control. In the reactions using the antibody against CDK4, a specific staining of mitotic cells was detectable. For E2F1, the percentage of tumor cells with a strong nuclear staining was estimated using a case of malignant melanoma as external positive control.
Statistics. Descriptive statistics, tests, and graphs were done with Statistica 6.0 (StatSoft, Hamburg, Germany) and the statistical software system R (34). Associations among the clinicopathologic, the molecular genetic, and the immunohistochemical variables were evaluated using the t test for independent samples (qRT-PCR), the two-sample Wilcoxon test (immunohistochemistry), and the Fisher's exact test in the case of categorical variables. To identify particular patterns of gene expression of all seven genes, a cluster analysis using the k-means algorithm was done. The k-means algorithm groups a given set of objects into a user-defined number k of clusters, such that the sum of within-cluster squared Euclidean distances is minimized (35) . The average silhouette width was used as a criterion to determine the optimal number of clusters (36) . Disease-free survival rates were plotted by the Kaplan-Meier method. Associations of patient and tumor variables with disease-free survival times were assessed with the log-rank test (in the case of categorical variables) and with univariate Cox proportional hazards models (qRT-PCR). For evaluation of correlation between qRT-PCR and immunohistochemistry, the one-sided Kendall's s test was used.
Results
Patients and follow-up. The clinicopathologic data of 38 patients (16 female, 22 male) with primary GIST are 37 patients and ranged from 2 to 84 months with a median of 32 months (mean, 35 F 22 months), during which 13 patients developed disease progression. Shorter disease-free survival was significantly associated with intestinal/mesenteric location (P = 2 Â 10 À3 ), tumor size >5 cm (P = 0.04), mitotic count >5/50 HPFs (P = 2 Â 10 À4 ), proliferation rate z10% (P = 2 Â 10 À5 ), and high-risk (P = 2 Â 10 À4 ). Mutation analysis. Mutation analysis was done of KIT exons 9, 11, 13, and 17 as well as PDGFRA exons 12 and 18 in all 38 GISTs. As expected in primary and untreated GISTs, we could not find more than one mutation in each GIST (Table 2) , confirming the mutually exclusive character of KIT or PDGFRA mutation (except in case 38, which carried both a KIT exon 11 mutation and a KIT exon 9 mutation). We found 27 GISTs with mutation of KIT (71.1%; 25 tumors with exon 11 mutation and 2 tumors with exon 9 mutation), whereas 4 GISTs had a mutation of the PDGFRA gene (10.5%; all tumors had exon 18 mutations). In the remaining 7 (18.4%) GISTs, all showing immunohistochemical c-kit expression, we could not find a mutation in any of the examined exons; thus, these cases were considered wild-type GISTs (for both KIT and PDGFRA). As a tendency, the different types of mutation seemed to be associated with clinical behavior. None of the four GISTs with PDGFRA mutation and only one of three GISTs with internal tandem duplication in the 3V-juxtamembrane domain of KIT developed disease progression. Both GISTs with KIT exon 9 mutation were of high risk, and one of them was clinically progressive. However, the frequency of these mutations was too low to reach statistical significance in the present study.
Quantitative reverse transcription-PCR. Significant associations between genotype and clinicopathologic variables on the one hand and the mRNA expression of individual genes on the other hand are summarized in Table 3 . GISTs with KIT mutation had higher mean expression of CDK4, RB1, MDM2, TP53, and E2F1 compared with GISTs with PDGFRA mutation (2.9-to 5.2-fold) or wild-type GISTs (2.2-to 2.7-fold). On the other hand, the mean expression of p16 INK4A and p14 ARF was significantly higher in wild-type GISTs than in GISTs with PDGFRA mutation (10.5-and 28.6-fold, respectively). Compared with gastric GISTs, intestinal tumors had higher mean expression of CDK4, RB1, MDM2, and TP53 (2.3-to 3.4-fold). Compared with GISTs with mitotic counts V5/50 HPFs, tumors with mitotic counts >5/50 HPFs had higher mean expression of CDK4 and E2F1 (2.1-and 4.0-fold, respectively) . Similarly, high-risk GISTs revealed higher mean expression of CDK4 and E2F1 than non-high-risk tumors (1.9-to 2.7-fold, respectively). Compared with nonprogressive GISTs, tumors with disease progression showed higher mean expression of CDK4, RB1, MDM2, TP53, and E2F1 (1.7-and 3.7-fold). In univariate Cox models, the differences in disease-free survival were statistically significant for CDK4, RB1, MDM2, TP53, and E2F1.
Clustering of gastrointestinal stromal tumors based on mRNA expression. Based on the similarity of the mRNA expression patterns of p16 INK4A , p14 ARF , CDK4, RB1, MDM2, TP53, and E2F1, the k-means cluster algorithm grouped the 38 GISTs into three clusters A, B, and C containing 17, 12, and 9 cases, respectively (Fig. 2) . GISTs from cluster A were characterized by a moderate to high mRNA expression of all seven analyzed genes p16
INK4A , p14 ARF , CDK4, RB1, MDM2, TP53, and E2F1. The GISTs of cluster B shared a low mRNA expression of p16 INK4A and p14 ARF combined with a high mRNA expression of the other five genes CDK4, RB1, MDM2, TP53, and E2F1. In contrast, GISTs of cluster C also showed a low mRNA expression of p16 INK4A and p14 ARF but together with a low mRNA expression of the other five genes CDK4, RB1, MDM2, TP53, and E2F1. There were significant differences in the distribution of tumors with KIT mutation, tumors with PDGFRA mutation, and tumors without mutation of KIT or PDGFRA among these three clusters (cluster A, 11/1/5; cluster B, 12/0/0; cluster C, 4/3/2; P = 0.01). As regards clinicopathologic variables, there was a trend for GISTs of cluster C to have lower mitotic counts and to be of low risk, but this trend did not reach statistical significance. However, there were significant differences in the distribution of gastric, intestinal, and mesenteric sites (cluster A, 12/3/2; cluster B, 5/6/1; cluster C, 9/ 0/0; P = 0.01) and the proportion of tumors showing disease progression (cluster A, 7 of 17; cluster B, 7 of 12; cluster C, none of 9; P = 0.01). The differences in disease-free survival were statistically significant (P = 0.03; Fig. 3 ).
Immunohistochemistry. Twenty-five of 38 (66%) cases were considered negative for p16 INK4A (Fig. 4A) , and there was a significant association between loss of p16 INK4A expression and high mitotic count (>5/50 HPFs; P = 0.03) or high risk (P = 0.04). Using the antibody against p14 ARF , 32% cases showed strong, 55% cases weak, and 13% cases no cytoplasmic staining (Fig. 4E ). For CDK4, there was a specific reactivity of mitotic (Fig. 4F) , and similar to mitotic count, higher protein expression of CDK4 was significantly associated with shorter disease-free survival (P = 0.008). The estimated percentage of E2F1-positive cells (Fig. 4D) ranged from 2% to 70% (mean, 9%), with a significant positive correlation between E2F1 staining and mitotic count (P = 0.02).
Correlation between quantitative reverse transcription-PCR and immunohistochemistry. For p16 INK4A , CDK4, and E2F1, there was a significant positive correlation between mRNA expression and immunohistochemical reactivity (P = 0.002, 0.04, and 0.0001, respectively). Comparing the three clusters derived from the k-means algorithm based on the mRNA expression with the semiquantitative immunohistochemical staining for p16 INK4A and p14 ARF , there also was a significant association detectable, in that clusters B and C (with low mean mRNA expression of p16 INK4A and p14 ARF ) contained a significantly higher proportion of tumors that were immunohistochemically negative for p16 INK4A (P = 0.01) and p14 ARF (P = 0.03).
Discussion
With respect to the close functional linkage of p16 INK4A , p14 ARF , CDK4, RB1, MDM2, TP53, and E2F1 combined in the CDKN2A tumor suppressor pathway, we used a cluster analysis based on the k-means algorithm to explore particular mRNA expression patterns of these genes in a series of 38 GISTs. This analysis yielded three subgroups of GISTs with distinct clinical behavior (Fig. 2) . The GISTs assigned to the first cluster A shared a moderate to high expression of all seven analyzed genes and revealed aggressive clinical behavior (Fig. 3) . Cluster B comprised GISTs with a low mRNA expression of the two CDKN2A transcripts p16
INK4A and p14 ARF combined with a very high expression of the other five members of the pathway, CDK4, RB1, MDM2, TP53, and E2F1. These tumors had a distinctly Fig. 3 . Kaplan-Meier plot for disease-free survival of 38 GISTs. The cluster analysis based on the mRNA expression of seven members of the CDKN2A network yielded three different subgroups of GISTs with distinct disease-free survival (P = 0.03). None of the 9 GISTs from cluster C showed aggressive clinical behavior, whereas 7 of 17 GISTs from cluster A did. The GISTs assigned to cluster B had the most unfavorable outcome (7 of 12). ARF along with also low mRNA expression of the other five genes CDK4, RB1, MDM2, TP53, and E2F1 revealed no aggressive clinical behavior. These observations confirm previous reports on a possible involvement of p16 INK4A in tumor progression of GISTs (7 -9) and furthermore implicate a role for the downstream members of the CDKN2A tumor suppressor pathway, CDK4, RB1, MDM2, TP53, and E2F1.
In general, malignant behavior of GISTs is associated with higher cell proliferation, and most schemes to prognostication of GISTs, including the current consensus approach, use mitotic count as a key variable (1 -3) . Herein, we showed that a higher mRNA and protein expression of E2F1 in GISTs was significantly associated with higher mitotic counts and higher proliferation rates. This is consistent with the critical role of E2F1 for initiation of S-phase entry and consecutive mitosis (19, 37, 38) . Furthermore, a high mRNA expression of E2F1 was significantly associated with aggressive clinical behavior and shorter disease-free survival. These results emphasize the crucial role of E2F1 in the control of cell proliferation and suggest E2F1 expression as a useful additional marker for prognostication of GISTs, as it has been proposed previously for non -small cell lung carcinomas (39) .
Another member of the CDKN2A tumor suppressor pathway, CDK4, has the ability of supporting the proliferative effect of E2F1 via phosphorylation of the RB1 protein. This is of special importance, as the release of free E2F1 in intact cells is closely controlled by its interaction partner RB1. In that CDK4 inhibits RB1 from eliminating E2F1, free E2F1 has the ability to up-regulate its own mRNA expression via positive feedback, thus enabling an uncontrollable amplification of itself (21) . Similar to E2F1, high mRNA expression of CDK4 was significantly correlated with high mitotic count and tumor progression. Immunohistochemistry revealed CDK4 solely in mitotic cells. Thus, CDK4 may critically contribute to the release of free E2F1 in GISTs. These observations further underline the close functional interconnection of the analyzed genes within the CDKN2A tumor suppressor pathway.
In normal cells, E2F1 is under negative feedback control of p14 ARF transactivation (23, 40, 41) with consecutive TP53 stabilization (22) and induction of p16 INK4A expression with CDK4 inactivation (24) , respectively (Fig. 1) . We observed the highest frequency of tumor progression in GISTs of cluster B with high expression of E2F1 and CDK4 but low expression of p16 INK4A and p14 ARF . The combined low mRNA expression of p16 INK4A and p14 ARF implicates a coregulation of these two alternative CDKN2A transcripts, which differ only by their first exon (11, 42) , and may represent genetic alteration of their common gene CDKN2A (7 -9). Thus, there is evidence for disrupted negative feedback control mechanisms for E2F1 with further uncontrolled cell growth in this subset of GISTs.
There is strong evidence that the genotype of KIT and PDGFRA in GISTs correlates with distinct regulation of downstream signaling cascades involving AKT, MAPK, and STAT signal transduction pathways (6), leading to distinguishable gene expression profiles in GISTs with KIT mutation, PDGFRA mutation, or wild-type GISTs (43 -45) . This may be the reason for the observed differences in clinical behavior. GISTs with KIT mutation have an adverse prognosis compared with wild-type GISTs (46, 47) , whereas mutations of PDGFRA appear preferentially in gastric GISTs and are associated with favorable prognosis (48, 49) . In this study, GISTs with KIT mutation had a significantly higher expression of CDK4, RB1, MDM2, TP53, and E2F1 compared with GISTs with PDGFRA mutation or wild-type GISTs. Furthermore, we found significant differences in the KIT/PDGFRA genotype among the three different clusters. All GISTs of the unfavorable cluster B carried a KIT exon 11 mutation, whereas GISTs of the more favorable cluster C had a disproportionate high incidence of PDGFRA mutation. From the four GISTs with KIT mutation in cluster C, two had the variant internal tandem duplication in the 3V end of KIT juxtamembrane domain, for which an association with favorable course has been reported (48) . A recent investigation of KIT signaling found stronger AKT phosphorylation in KIT exon 11 mutant GISTs, which was correlated with a higher proliferation rate and a presumably more aggressive clinical behavior (6) . Notably, AKT activation was shown to inhibit E2F1-induced apoptosis, suggesting a negative feedback loop involving E2F1 and AKT (50, 51) . Thus, the GISTs with KIT exon 11 mutation assigned to cluster B may represent a subgroup of GISTs with up-regulated expression of E2F1, which may be partially due to interrupted negative feedback control of p16 INK4A /p14 ARF . Whether as a consequence of activated AKT in these KIT exon 11 mutated GISTs such upregulation of E2F1 leads to increased cell proliferation instead of apoptosis remains to be determined.
Tumor site in GISTs is viewed as an independent prognostic variable, with tumors arising from the stomach generally having a better prognosis than those arising from the intestinum (3). This perception was further supported by a recent study, which revealed distinct gene expression profiles of gastric and intestinal GISTs (43) . Indeed, we also found a significantly higher mRNA expression of CDK4, RB1, MDM2, and TP53 in intestinal GISTs, suggesting that GISTs of intestinal sites may be genetically distinct from gastric GISTs. Furthermore, all GISTs of the favorable cluster C were of gastric site, whereas the unfavorable cluster B contained a disproportionate high number of intestinal GISTs. Whether this observation reflects an alternate route of the CDKN2A network in intestinal GISTs, or represents a consequence of the differences in the distribution of mutation types among the three clusters, cannot be clearly distinguished. However, up-regulated expression of E2F1 may occur in GISTs of both gastric and intestinal sites and may carry prognostic significance for GISTs irrespective of site.
In conclusion, there is evidence for molecular alterations of the CDKN2A tumor suppressor pathway to contribute to tumor progression in GISTs. The common and critical link of alternate routes within this network is E2F1, which finally controls progression of a quiescent state to proliferation. We herein suggest that up-regulated expression of E2F1 is of prognostic relevance in GISTs, and determination of the E2F1 expression status may be a helpful prognosticator in predicting clinical behavior. Eventually, E2F1 or other genes within the CDKN2A pathway may provide potential targets for new molecular-based therapies in GISTs. 
